Contributors; Preface; Contents; Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development; 1 Oncogenes, Tumor Suppressors and Targeted Therapeutics; 2 Somatic Copy Number Alterations and Coding Mutation Frequencies According to Lung Cancer Subtype; 2.1 Lung Adenocarcinoma; 2.1.1 EGFR; 2.1.2 KRAS; 2.1.3 BRAF; 2.1.4 HER2; 2.1.5 MET; 2.2 Squamous Cell Lung Cancer; 2.2.1 Somatic Copy Number Alterations in Squamous Cell Lung Cancer; 2.2.2 Somatic Coding Mutations in Squamous Cell Lung Cancer; 2.3 Small Cell Lung Cancer; 3 Genomic Translocations and Expressed Fusion Genes; 3.1 ALK

3.2 ROS13.3 RET; 4 Challenges and Conclusions; References; Emerging Biomarkers in Personalized Therapy of Lung Cancer; 1 Introduction; 2 ROS1; 3 RET; 4 MET; 5 HER 2; 6 BRAF; References; Epithelial Mesenchymal Transition in Aggressive Lung Cancers; 1 Epithelial Mesenchymal Transition in Cancer: Overview; 2 Epithelial Mesenchymal Transition in Physiological Processes and Cancer; 3 Epithelial Mesenchymal Transition in Primary Tumor and Metastatic Dissemination; 4 Epithelial Mesenchymal Transition in Lung Cancer; 4.1 Epithelial Mesenchymal Transition and Prognosis in Lung Cancer

4.2 Epithelial Mesenchymal Transition and Lung Cancer Progression4.3 Epithelial Mesenchymal Transition and Drug Resistance in Lung Cancer; 5 Therapeutic Potential of Targeting Epithelial Mesenchymal Transition in Lung Cancer; 6 Future Perspectives; References; The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer; 1 Introduction; 2 Cancer Stem Cells of the Lungs; 2.1 Markers Defining Lung CSCs and Their Potential Biological Implications; 2.1.1 CD133; 2.1.2 ALDH; 2.1.3 ABCG2; 2.1.4 Nanog; 2.2 Therapeutic Targeting of Lung CSC Markers; 3 Drug-Resistance

3.1 Role of EMT in Drug-Resistance3.2 Role of CSCs in Drug-Resistance; 4 The Role of miRNAs; 4.1 MicroRNAs Associated with Chemoresistance; 4.1.1 miR-212; 4.1.2 The let-7 Family; 4.1.3 miRNAs Associated with EGFR; 4.2 MicroRNAs Associated with CSCs; 4.2.1 miR-34a; 4.2.2 miR-21; 4.2.3 The miR-200 Family; 5 Natural Agents and Their Synthetic Derivative as Anti-cancer Compounds; 5.1 BR-DIM; 5.2 Curcumin; 5.3 CDF; 6 Conclusions: The Future of CSCs and CSC-Targeted Treatment; References; The Microenvironment of Lung Cancer and Therapeutic Implications; 1 The Tumor Microenvironment: An Overview

2 TME in Lung Cancer Prognosis3 TME in Lung Cancer Progression and Metastasis; 3.1 Cancer-Associated Fibroblasts (CAFs); 3.2 Endothelial Cells; 3.3 Hypoxia in Lung Cancer; 3.4 Inflammation; 3.5 Immune Cells; 3.5.1 T-Cells; 3.5.2 γδ T Cells; 3.5.3 Myeloid-Derived Suppressor Cells; 4 TME of Premetastatic Niche in the Lung; 5 The Contribution of TME to Therapeutic Resistance; 5.1 Contribution of TME to Resistance to Radiation Therapy; 5.2 Contribution of TME to Resistance to Antiangiogenic Therapies and EGFR-TKIs; 6 The TME as a Therapeutic Target in Lung Cancer